Abstract
Introduction

46
The need to formulate drugs that have narrow therapeutic indices (for instance immunosuppressants or blood thinners), the increasing importance of proteomic and 
63
It is 3D printing (3DP) technology however that offers perhaps the greatest potential 64 to revolutionize the future of pharmaceutical manufacturing (Yu et al, 2008; Wang, that it cannot print hollow objects, because free powder will always be contained in 74 the cavity, although even this effect has been exploited to fabricate fast-dissolving 75 devices comprising powder contained in a polymeric shell (Yu et al, 2009a,b 
79
The most recent 3DP technology is fused-filament (FF) printing, wherein a polymer 80 strand is heated and extruded through a small tip (typically 50-100 µm) and then 81 solidified on a build plate. FF technology has the significant advantages of cost
82
(typical systems cost between £800-2000), the ability to fabricate hollow objects and 83 the utility to print a range of polymers. The printer feedstock is an extruded polymer 84 filament, typically 1.75 -3 mm in diameter. One of the prime benefits of FF 3DP is 85 that it is possible in principle to incorporate drug into the polymer filament so that the 86 printed dosage form is drug loaded.
87
To our knowledge, there has been no demonstration on the use of FF printing to 88 manufacture drug-loaded unit dosage forms, although recent work using a similar 89 system to print a paste has been reported (Khaled et al, 2014). Hence, the specific 90 aims of this work were evaluate a method to load drug into the polymer filament, to 91 print drug-loaded tablets using an FF 3DP and to explore whether varying the print 92 settings enabled control over the dissolution kinetics of the final tablet and so offer a 
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Materials and Methods
97
Polyvinyl alcohol (PVA, a water-soluble synthetic polymer of formula (C 2 H 4 O) n ) was 
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Equation 2 159 
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The tablet template was imported into the Makerware software prior to printing as a 219 stereolithography (.stl) file. This file type encodes only the surface data (or shell) of 220 the object to be printed. It is necessary for the 3DP software to define the thickness
221
of the shell (so that there is an object of some physical size to be printed) but in 222 essence a hollow object will be printed. To increase the mechanical strength of the 223 object, the user can select an infill percentage to be used during printing (the infill 224 percentage is the degree to which the printer will pack the void space with polymer 225 and will vary from 0, empty, to 100, solid). Greater infill percentages will result in 226 stronger objects. It follows that there is the potential to use the infill percentage to 227 modulate the physical properties of the 3DP tablet, and so the dissolution profile. 
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It can be seen from Table 1 
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For dissolution testing tablets were selected with low (10%), medium (50%) and high 
254
Pictures of tables obtained after dissolution show a reduction of size and an
255
apparently homogenous distribution of the drug inside the tablet during the 256 dissolution process (Figure 6 ). According to the pictures, the release of the drug 257 seems to be mediated mainly by an erosion process.
259
Conclusion
260
We have demonstrated the feasibility of using FF 3DP to fabricate drug-loaded 
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